3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Serotonin Syndrome
2
Carcinoid Tumor
2
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors in Lung
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
lanreotide
1
cabozantinib
1
X-Rays
1
Sunitinib
1
Specimen Handling
1
Phantoms, Imaging
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenoma, Islet Cell
×
lanreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled